Breast Cancer

Arms 7 and 8 of the BEGONIA trial showed comparable outcomes for patients with different PD-L1 expression when receiving dato-DXd/durvalumab for TNBC.

A total of 46.6% of patients showed a favorable response to ultrahypofractionation radiotherapy for locally advanced breast cancer.

Sarah Poland, MD, discussed the landscape of immunotherapy in breast cancer, including clinical trial data, the rise of ADCs, and strategies for managing AEs.

A predetermined change control plan was authorized as part of the premarket approval, allowing for AI enhancements without the need for FDA oversight.

In the phase 3 neoCARHP trial, THP showed noninferior pathologic complete response rates compared with TCbHP in patients with HER2-positive breast cancer.

Patrick Borgen, MD, discussed using ctDNA for “molecular interception” to de-escalate surgery and minimize AEs in biology-driven breast cancer care.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

The EGFR/HER3 bispecific ADC met the primary end points of PFS and OS in patients with advanced triple-negative breast cancer.

A novel agent in combination with olaparib has been granted fast track designation by the FDA for germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.

Learn how ctDNA monitoring predicts breast cancer recurrence and detects ESR1/PIK3CA resistance, enabling earlier, personalized therapy switches.

A Prescription Drug User Fee Act date of December 18, 2026, has been set for giredestrant plus everolimus in ER+, HER2–, ESR1-mutated breast cancer.

Since 2003, breast cancer has been one of the black box warnings associated with hormone replacement therapy for women experiencing menopause.

Sunil W. Dutta, MD, discussed hypofractionation in breast reconstruction and why clinical follow up remains a key "soft skill" in an AI-driven field.

In this review, we highlight pivotal trials that have informed current practice and ongoing trials that may inform the therapeutic landscape in the coming years.

Surgical updates for invasive breast cancer from the NCCN Breast Cancer meeting revealed insights on neoadjuvant endocrine therapy and SLNB omission.

Certain strategies are needed to improve clinical trial diversity, focusing on building patient trust, increasing workforce representation, and reducing logistical burdens.

Parul Barry, MD, discusses advances such as ultrahypofractionated radiation and the growing role of AI in streamlining workflows for breast cancer care.

According to Jean L. Wright, MD, FASTRO, the flow of new information and research pertaining to ductal carcinoma in situ is constant.

The implementation of AI into radiomics may help predict the likelihood of response to therapies among patients undergoing breast cancer treatment.

Kathie-Ann Joseph, MD, MPH, FACS, described the clinical criteria for nipple-sparing mastectomies and oncoplastic surgery, focusing on tumor-to-nipple distance and oncologic safety for breast cancer patients.

J. Isabelle Choi, MD, outlined evidence-based strategies for radiation dose escalation in locoregionally advanced breast cancer.

Ifeoma Dikeocha, PhD, discussed how metabolic restriction and fasting-mimicking diets can help optimize chemotherapy outcomes in breast cancer.

Ifeoma Dikeocha, PhD candidate, explains why triple-negative breast cancer is uniquely sensitive to fasting mimicking diets.

A PDUFA date in the second quarter of 2026 has been set for Dato-DXd in patients with unresectable or metastatic TNBC.

Kathie-Ann Joseph, MD, MPH, FACS, explored evolving surgical strategies for inflammatory breast cancer and phyllodes tumors.